|
|
| Product Name: | CYY292 | | Synonyms: | CYY292;2,4-Pyrimidinediamine, N4-1H-indazol-6-yl-N2-[3-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-5-methyl- | | CAS: | 2644673-04-9 | | MF: | C24H28N8O | | MW: | 444.53 | | EINECS: | | | Product Categories: | | | Mol File: | 2644673-04-9.mol |  |
| | CYY292 Chemical Properties |
| Boiling point | 714.7±70.0 °C(predicted) | | density | 1.318±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | solubility | Ethanol: Slightly soluble
Methanol: Slightly soluble | | form | Solid | | pka | 14.22±0.40(predicted) | | color | White to off-white |
| | CYY292 Usage And Synthesis |
| Uses | CYY292 is an FGFR1 inhibitor that specifically targets the FGFR1/AKT/Snail pathway in GBM cells. CYY292 dose-dependently inhibits cancer cell proliferation, epithelial-mesenchymal transition, stemness, invasion, and migration in vitro[1]. | | References | [1] Bi Y, et al. A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis. Genes Dis. 2023 Apr 3;11(1):479-494. DOI:10.1016/j.gendis.2023.02.035
[2] XIAOJING CHEN, ZHIGUO LIU* Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma[J]. Journal of Medicinal Chemistry, 2022, 65 7: 5374-5391. DOI: 10.1021/acs.jmedchem.1c01732 |
| | CYY292 Preparation Products And Raw materials |
|